Literature DB >> 16546546

Tuberculosis drug development pipeline: progress and hope.

Melvin Spigelman1, Stephen Gillespie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16546546     DOI： 10.1016/S0140-6736(06)68388-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Control of Extensively Drug-Resistant Tuberculosis (XDR-TB): A Root Cause Analysis.

Authors:  Jennifer Prah Ruger
Journal:  Glob Health Gov       Date:  2010-04-01

Review 3.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 4.  Recent trends on hydrogel based drug delivery systems for infectious diseases.

Authors:  Arti Vashist; Ajeet Kaushik; Atul Vashist; Rahul Dev Jayant; Asahi Tomitaka; Sharif Ahmad; Y K Gupta; Madhavan Nair
Journal:  Biomater Sci       Date:  2016-10-18       Impact factor: 6.843

5.  CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

Authors:  Payam Nahid; Jussi Saukkonen; William R Mac Kenzie; John L Johnson; Patrick P J Phillips; Janet Andersen; Erin Bliven-Sizemore; John T Belisle; W Henry Boom; Annie Luetkemeyer; Thomas B Campbell; Kathleen D Eisenach; Richard Hafner; Jeffrey L Lennox; Mamodikoe Makhene; Susan Swindells; M Elsa Villarino; Marc Weiner; Constance Benson; William Burman
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

Review 6.  Tuberculosis as part of the natural history of HIV infection in developing countries.

Authors:  Gabriel Chamie; Annie Luetkemeyer; Edwin Charlebois; Diane V Havlir
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

Review 7.  Antituberculosis therapy for 2012 and beyond.

Authors:  Michael Lauzardo; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2012-02-15       Impact factor: 3.889

8.  Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.

Authors:  Diane J Ordway; Crystal A Shanley; Megan L Caraway; Eileen A Orme; Daniel S Bucy; Laurel Hascall-Dove; Marcela Henao-Tamayo; Marisa R Harton; Shaobin Shang; David Ackart; Susan L Kraft; Anne J Lenaerts; Randall J Basaraba; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

9.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

10.  Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.

Authors:  Shelley E Haydel
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.